摘要
人附睾分泌蛋白（HE4）mRNA在卵巢癌组织中高表达，其量和卵巢癌的组织类型有类；血清HE4检测在卵巢早期诊断中与糖类抗类125（CA125）相比敏感度与特异度相当，因假阳性率比CA125低而优于后者；组合标志物中，CA125和HE4联合检测的敏感性最高；HF4可用于监测卵巢癌的疗效和复发；HE4不仅是卵巢癌肿瘤标志物，也是卵巢癌靶向治疗的潜在靶点。
Human epididymis gene product 4 （HE4）mRNA highly expressed in oarian cancer tissue and the quantity was associated with the type of the ovarian cancer;The serum HE4 had the same specificity and sensitivity in the early diagnosis of oarian cancer compared with CA125, and the HE4 had an advantage over the CA125 in that it was less frequently positive in patients with nonmalignant disease ; the combination of HE4 and CA125 yielded higher sensitivity;The serum tumor marker HFA is an excellent marker for determining response to treatment and for the detection of early recurrence of disease in patients with epithelial ovarian cancer;liE4 is not only a serological tumor biomarker but also a target for gene-based therapy of ovarian cancer.
出处
《国际肿瘤学杂志》
CAS
2010年第3期222-225,共4页
Journal of International Oncology
关键词
卵巢肿瘤
肿瘤标记
生物学
附睾分泌蛋白类
酶联免疫吸附测定
Ovarian cancer
Tumor marker,biological
Epididymal secretory proteins
Enzyme-linked immunosorbent Assay
